ERBB2 and non-small cell lung carcinoma: The literature reports that the most common tumor types developing brain metastases respond better with a combination of SRS and targeted therapies, including non-small cell lung cancer, HER-2-positive breast cancer, endocrine receptor-positive breast cancer, melanoma, and renal cell carcinoma [27].